论文部分内容阅读
[目的]了解已接受术后辅助化疗的非小细胞肺癌(NSCLC)患者对辅助化疗的评价和选择倾向。[方法]调查2006年11月1日～2009年3月31日间接受术后辅助化疗的NSCLC60例。调查内容包括患者对辅助化疗的评价,患者在假设病理ⅠB期、Ⅱ期和ⅢA期条件下可接受辅助化疗带来的最小生存率和中位生存期。[结果]93.3%患者认为辅助化疗值得做。约70%患者愿意接受辅助化疗以获得生存期延长1年或者5年生存率提高10%。曾出现化疗重度毒副反应、ⅢA期和经济状况差的患者要求辅助化疗带来的生存获益更高。[结论]多数患者能够接受术后辅助化疗带来的益处和毒性反应。
[Objective] To investigate the evaluation and selection tendencies of adjuvant chemotherapy in patients with non-small cell lung cancer (NSCLC) who have received postoperative adjuvant chemotherapy. [Method] Investigate 60 cases of NSCLC receiving postoperative adjuvant chemotherapy from November 1, 2006 to March 31, 2009. Surveys included patient evaluations of adjuvant chemotherapy, and minimal survival and median survival for patients undergoing adjuvant chemotherapy assuming stage IB, II, and IIIA. [Results] 93.3% of patients considered adjuvant chemotherapy worth doing. Approximately 70% of patients are willing to receive adjuvant chemotherapy to achieve a one-year extension of survival or a 10% increase in 5-year survival. Severe chemotherapeutic side effects have occurred and patients with stage IIIA and poor health require additional benefit from adjuvant chemotherapy. [Conclusion] Most patients are able to accept the benefit and toxicity of postoperative adjuvant chemotherapy.